|
Theratechnologies Inc. (THTX) DCF Valoración
CA | Healthcare | Drug Manufacturers - Specialty & Generic | NASDAQ
|
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
Theratechnologies Inc. (THTX) Bundle
¡Agilice su análisis y mejore la precisión con nuestra calculadora DCF (THTX)! Utilizando datos reales de Theratechnologies Inc. y suposiciones personalizables, esta herramienta le permite pronosticar, analizar y evaluar (THTX) como un inversor experimentado.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 43.8 | 45.8 | 48.4 | 55.5 | 56.7 | 60.5 | 64.6 | 69.0 | 73.6 | 78.6 |
| Revenue Growth, % | 0 | 4.49 | 5.71 | 14.66 | 2.13 | 6.75 | 6.75 | 6.75 | 6.75 | 6.75 |
| EBITDA | .0 | -6.4 | -11.9 | -19.3 | -7.2 | -10.4 | -11.1 | -11.8 | -12.6 | -13.5 |
| EBITDA, % | 0.04431157 | -13.89 | -24.57 | -34.81 | -12.61 | -17.17 | -17.17 | -17.17 | -17.17 | -17.17 |
| Depreciation | 5.2 | 6.1 | 5.9 | 8.3 | 2.3 | 6.9 | 7.3 | 7.8 | 8.3 | 8.9 |
| Depreciation, % | 11.86 | 13.38 | 12.29 | 15.03 | 4.04 | 11.32 | 11.32 | 11.32 | 11.32 | 11.32 |
| EBIT | -5.2 | -12.5 | -17.8 | -27.7 | -9.4 | -17.2 | -18.4 | -19.6 | -21.0 | -22.4 |
| EBIT, % | -11.82 | -27.28 | -36.86 | -49.84 | -16.65 | -28.49 | -28.49 | -28.49 | -28.49 | -28.49 |
| Total Cash | 28.2 | 14.4 | 28.0 | 22.9 | 28.0 | 29.6 | 31.6 | 33.7 | 36.0 | 38.4 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 7.0 | 9.1 | 7.6 | 8.6 | 9.4 | 10.1 | 10.8 | 11.5 | 12.3 | 13.1 |
| Account Receivables, % | 16 | 19.96 | 15.65 | 15.42 | 16.57 | 16.72 | 16.72 | 16.72 | 16.72 | 16.72 |
| Inventories | 14.5 | 17.4 | 20.2 | 13.7 | 4.2 | 17.5 | 18.7 | 20.0 | 21.3 | 22.8 |
| Inventories, % | 33.11 | 38.07 | 41.74 | 24.59 | 7.42 | 28.98 | 28.98 | 28.98 | 28.98 | 28.98 |
| Accounts Payable | 9.1 | 12.1 | 10.8 | 8.9 | 4.8 | 11.4 | 12.2 | 13.0 | 13.9 | 14.8 |
| Accounts Payable, % | 20.73 | 26.51 | 22.24 | 16.1 | 8.55 | 18.82 | 18.82 | 18.82 | 18.82 | 18.82 |
| Capital Expenditure | -2.5 | .0 | -.1 | -.7 | -1.3 | -1.1 | -1.2 | -1.3 | -1.4 | -1.5 |
| Capital Expenditure, % | -5.73 | -0.04844594 | -0.23774 | -1.23 | -2.22 | -1.89 | -1.89 | -1.89 | -1.89 | -1.89 |
| Tax Rate, % | -1.79 | -1.79 | -1.79 | -1.79 | -1.79 | -1.79 | -1.79 | -1.79 | -1.79 | -1.79 |
| EBITAT | -5.2 | -12.5 | -17.9 | -27.9 | -9.6 | -17.2 | -18.4 | -19.6 | -21.0 | -22.4 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -14.9 | -8.4 | -14.6 | -16.5 | -4.1 | -19.1 | -13.4 | -14.3 | -15.3 | -16.3 |
| WACC, % | 15.05 | 15.05 | 15.05 | 15.05 | 15.05 | 15.05 | 15.05 | 15.05 | 15.05 | 15.05 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -52.9 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -17 | |||||||||
| Terminal Value | -128 | |||||||||
| Present Terminal Value | -63 | |||||||||
| Enterprise Value | -116 | |||||||||
| Net Debt | 17 | |||||||||
| Equity Value | -133 | |||||||||
| Diluted Shares Outstanding, MM | 26 | |||||||||
| Equity Value Per Share | -5.07 |
What You Will Get
- Real Theratechnologies Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures.
- Full Customization: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
- Instant Valuation Updates: Automatic recalculations to analyze the impact of changes on Theratechnologies’ fair value.
- Versatile Excel Template: Tailored for quick edits, scenario testing, and detailed projections.
- Time-Saving and Accurate: Skip building models from scratch while maintaining precision and flexibility.
Key Features
- Comprehensive DCF Calculator: Features detailed unlevered and levered DCF valuation models tailored for Theratechnologies Inc. (THTX).
- WACC Calculator: Pre-configured Weighted Average Cost of Capital sheet with adjustable inputs specific to Theratechnologies Inc. (THTX).
- Customizable Forecast Assumptions: Adjust growth rates, capital expenditures, and discount rates to fit Theratechnologies Inc. (THTX) projections.
- Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios pertinent to Theratechnologies Inc. (THTX).
- Interactive Dashboard and Charts: Visual representations summarize essential valuation metrics for streamlined analysis of Theratechnologies Inc. (THTX).
How It Works
- Download the Template: Get instant access to the Excel-based THTX DCF Calculator.
- Input Your Assumptions: Adjust yellow-highlighted cells for growth rates, WACC, margins, and more.
- Instant Calculations: The model automatically updates Theratechnologies’ intrinsic value.
- Test Scenarios: Simulate different assumptions to evaluate potential valuation changes.
- Analyze and Decide: Use the results to guide your investment or financial analysis.
Why Choose This Calculator for Theratechnologies Inc. (THTX)?
- Accuracy: Leverages real Theratechnologies financial data for precise calculations.
- Flexibility: Allows users to easily adjust and test various input parameters.
- Time-Saving: Eliminates the need to create a DCF model from the ground up.
- Professional-Grade: Crafted with the expertise and precision typically expected at the CFO level.
- User-Friendly: Intuitive design makes it accessible for users without extensive financial modeling skills.
Who Should Use This Product?
- Investors: Evaluate Theratechnologies Inc.'s (THTX) market position before making investment decisions.
- CFOs and Financial Analysts: Optimize valuation methodologies and validate financial forecasts for THTX.
- Biotech Entrepreneurs: Understand the valuation strategies of publicly traded biotech firms like Theratechnologies Inc. (THTX).
- Consultants: Create comprehensive valuation analyses and reports for clients in the biotech sector.
- Students and Educators: Utilize current data to learn and teach valuation practices relevant to the biotech industry.
What the Template Contains
- Historical Data: Includes Theratechnologies Inc.'s (THTX) past financials and baseline forecasts.
- DCF and Levered DCF Models: Detailed templates to calculate Theratechnologies Inc.'s (THTX) intrinsic value.
- WACC Sheet: Pre-built calculations for Weighted Average Cost of Capital.
- Editable Inputs: Modify key drivers like growth rates, EBITDA %, and CAPEX assumptions.
- Quarterly and Annual Statements: A complete breakdown of Theratechnologies Inc.'s (THTX) financials.
- Interactive Dashboard: Visualize valuation results and projections dynamically.